What are CYSLTR2 antibodies?
Anti-CYSLTR2 antibodies are immunoglobulins that specifically recognize and bind CYSLTR2, the gene encoding cysteinyl leukotriene receptor 2 in humans. In research applications, these antibodies are used to detect CYSLTR2 in tissue samples, cell lysates, and cultured cells. CYSLTR2 is a G protein-coupled receptor for cysteinyl leukotrienes that signals through a phosphatidylinositol-calcium second messenger system, with cysteinyl leukotrienes C4 and D4 acting as its most potent ligands. Detecting CYSLTR2 supports research into leukotriene-driven inflammation, bronchoconstriction, and itch signaling.
Catalog highlights and purchasing considerations
About the Biocompare CYSLTR2 antibody catalog
The Biocompare antibody search tool lists anti-CYSLTR2 antibodies from a range of suppliers, available in unconjugated and fluorophore- or enzyme-conjugated formats. Western blot is the most common validated application among these listings, followed by immunofluorescence and ELISA. Several CYSLTR2 antibodies mentioned here have been cited across a range of inflammation research, including montelukast treatment of bronchiolitis obliterans syndrome after hematopoietic cell transplantation, a basophil-neuronal signaling axis driving itch, and modulation of cysteinyl leukotriene receptor expression by IL-4 and interferon-gamma.
Considerations when choosing a CYSLTR2 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.